The peak window can be represented mechanistically as the region of a sildenafil concentration–time trajectory surrounding maximum concentration formation. It is not a single clinical moment; it is a PK/PD geometry defined by the approach toward peak concentration, the location of Tmax, the magnitude of Cmax, the shape of the rising and declining phases, distribution behavior, and the way concentration is mapped onto a modeled pharmacodynamic response. The rising phase reflects the balance between systemic input and disposition, while the peak region emerges when input and disposition become sufficiently balanced that concentration reaches a maximum. Tmax provides the temporal descriptor of that maximum, whereas Cmax provides its magnitude. Distribution can modify the shape and persistence of concentrations around the peak, while concentration–effect coupling determines how the same concentration trajectory is represented in a modeled PD system. These components therefore describe different dimensions of one peak-phase structure rather than separate clinical endpoints. A mechanistic comparison of this geometry can distinguish timing, magnitude, slope, persistence, and PD coupling without assigning therapeutic meaning to any individual feature. The resulting construct is a model of peak-phase PK/PD behavior, not a statement about real-world effectiveness. See the broader PK comparison framework for related concentration–time descriptors.
The rising phase is the portion of the concentration–time trajectory in which systemic sildenafil concentration is increasing toward its maximum. Its geometry depends strongly on the rate and timing of drug input relative to concurrent distribution and elimination processes. Dissolution determines how rapidly material becomes available for subsequent absorption, while gastric emptying can influence when dissolved material reaches absorptive regions of the gastrointestinal tract. Once systemic entry begins, the absorption rate constant and the temporal distribution of input determine the steepness, curvature, and duration of the ascending concentration phase. A concentrated input can generate a steeper rising segment, whereas a temporally distributed input can produce a broader and less steep approach to the maximum. The peak window therefore begins conceptually with the transition from early concentration formation into the region where the rising slope progressively decreases. The exact shape is not determined by absorption alone because disposition continues throughout the ascending phase. Distribution and metabolic clearance can remove drug from the central compartment while absorption is still adding drug to it. The observed trajectory is consequently an input–disposition composite rather than a direct readout of absorption rate alone. The mechanistic role of absorption is therefore to establish much of the temporal structure of the approach to peak.
Tmax is the temporal descriptor identifying when the modeled plasma concentration reaches its maximum. In peak-window geometry, Tmax provides a reference point around which the peak phase can be described, but it does not specify the magnitude of the peak or the duration of concentration persistence around it. Mathematically, the maximum occurs where the net rate of concentration change transitions from positive to negative, meaning systemic input has ceased to exceed total disposition sufficiently to continue increasing concentration. Before Tmax, the ascending input component dominates the net trajectory; near Tmax, input and disposition approach balance; after Tmax, disposition exceeds remaining input and concentration begins to decline. Changes in dissolution timing, gastric emptying, absorption rate, distribution, or clearance can therefore shift Tmax by changing the relative timing of these processes. A shift in Tmax does not necessarily imply a proportional change in Cmax because temporal and magnitude descriptors arise from related but distinct features of the concentration–time curve. Two modeled trajectories can reach similar peak magnitudes at different times, or reach different peak magnitudes at similar times. Tmax is therefore best interpreted as the temporal coordinate of peak formation within the PK trajectory. The Tmax parameter provides this timing descriptor without converting it into a clinical interpretation.
Cmax represents the maximum modeled plasma concentration reached during a sildenafil concentration–time trajectory. Within peak-window geometry, it forms the vertical dimension of the peak: it describes how high the concentration curve rises, whereas Tmax describes when that maximum occurs. Cmax emerges from the integrated relationship between the amount entering systemic circulation, the rate at which that input arrives, the extent of bioavailability, and simultaneous distribution and elimination. A faster input process can increase the steepness of the rising phase and alter the magnitude of the maximum, but the resulting Cmax also depends on how much drug reaches the systemic compartment and how rapidly it is removed or redistributed during the same interval. Consequently, Cmax cannot be interpreted independently of the surrounding concentration–time geometry. A high or low modeled Cmax may coexist with either an earlier or later Tmax depending on the balance between input and disposition. The width of the peak region also cannot be inferred from Cmax alone because persistence around the maximum depends on the slopes before and after the peak. Cmax is therefore a magnitude descriptor embedded within a multidimensional PK trajectory. The Cmax parameter captures this vertical component of peak formation without assigning therapeutic or clinical meaning to the magnitude.
Distribution contributes to peak-phase geometry by determining how sildenafil moves between the central circulating compartment and peripheral distribution spaces during the same interval in which absorption and elimination are occurring. During the rising phase, distribution can reduce the concentration remaining in the central compartment as drug moves into tissues, while later redistribution can return drug toward the central compartment as concentration gradients change. These processes can influence both the height and shape of the concentration curve around Tmax. A relatively rapid distribution phase can alter the early concentration trajectory before the terminal decline becomes dominant, while slower equilibration can extend concentration transitions across a broader temporal region. The effect is therefore not simply an increase or decrease in peak concentration; distribution can modify curvature, peak sharpness, and the relationship between the ascending and descending portions of the trajectory. In a compartmental representation, the central compartment may reach its maximum while peripheral compartments continue approaching equilibrium, creating a peak structure that reflects incomplete distributional equilibration. Redistribution can subsequently contribute to the post-peak shape without representing new systemic input. This distinction is important because the plasma peak is a compartment-specific feature of the full PK system. The broader distribution process therefore provides a mechanistic basis for interpreting peak persistence and decline without equating either feature with a clinical peak.
The PK-to-PD relationship converts concentration geometry into a modeled pharmacodynamic trajectory through concentration–effect coupling. During the peak window, increasing sildenafil concentration can correspond to an increasing modeled PD signal when the concentration–effect relationship is represented as a monotonic function. As concentration approaches Cmax, the modeled PD trajectory may approach its corresponding upper region depending on the assumed coupling function, receptor or enzyme interaction, and downstream pathway representation. The PD trajectory does not have to be geometrically identical to the plasma concentration trajectory because concentration–effect relationships can introduce nonlinear scaling, saturation, or temporal separation between plasma concentration and modeled response. For sildenafil, mechanistic PD representation can include PDE5 inhibition and downstream modulation of the NO–sGC–cGMP pathway, but the peak-window construct remains centered on how concentration is translated into modeled pathway activity. Thus, Tmax is a PK time coordinate, Cmax is a PK magnitude coordinate, and the modeled PD peak is a separate output generated by the concentration–effect relationship. A concentration maximum does not automatically establish an identical PD maximum at the same instant. The PK and PD curves can instead be compared as coupled trajectories whose relationship depends on the specified mechanistic model. The PD summary provides the corresponding pharmacodynamic framework.
Peak-window geometry is inherently variable because each component of the concentration–time and concentration–effect system can vary independently or interactively. Absorption variability can change the timing, steepness, and duration of the rising phase, shifting the location or shape of the concentration maximum. Distribution variability can modify the extent of early central-compartment depletion, redistribution, and post-peak persistence. Metabolic variability can alter the rate at which concentration begins to decline once systemic input becomes insufficient to maintain the ascending trajectory. These PK changes can modify Tmax, Cmax, peak curvature, and the width of the concentration region surrounding the maximum. PD variability introduces another layer because the same concentration geometry can be mapped onto different modeled response geometries when concentration–effect parameters differ. A narrower concentration peak does not necessarily produce a proportionally narrower PD peak, and a broader concentration trajectory does not necessarily imply equivalent broadening of the modeled PD signal. The complete peak window is therefore a composite construct produced by input, distribution, metabolism, elimination, and concentration–effect coupling. PK variability describes variability in the concentration trajectory, while PD variability describes variability in how that trajectory is translated into pharmacodynamic behavior.
The rising phase is defined by the period in which the net plasma concentration of sildenafil is increasing toward its maximum. Its steepness depends on the relationship between systemic input and simultaneous disposition. When absorption supplies drug to the central compartment faster than distribution and elimination remove it, concentration rises. As disposition progressively offsets input, the slope becomes less positive and the trajectory bends toward Tmax. The resulting geometry therefore contains information about both the rate of absorption and the magnitude of competing disposition processes. A rapid, concentrated input can create a steeper ascending segment, whereas slower or temporally distributed input can broaden the approach to the peak. The rising phase is not equivalent to Tmax itself; it is the trajectory that leads into the temporal peak coordinate. Distribution can further modify the observed plasma slope by transferring drug away from the central compartment during this period. Elimination also acts continuously rather than beginning after the peak. Consequently, peak formation represents the outcome of concurrent processes rather than a sequential sequence in which absorption stops before disposition begins. The mechanistic contribution of absorption is primarily expressed through the timing, rate, and extent of systemic input that establishes the ascending concentration geometry.
Dissolution is an upstream determinant of when drug becomes available for subsequent absorption and therefore can influence the temporal structure of the rising concentration phase. Tablet disintegration exposes the active ingredient to the surrounding gastrointestinal environment, after which dissolution transfers drug into a form available for absorption. If dissolution proceeds over a broader interval, systemic input can become temporally distributed rather than concentrated into a narrower input phase. That distribution can flatten or broaden the early concentration trajectory and shift the point at which the curve enters the peak region. The effect is mechanistically upstream: dissolution does not directly define Tmax or Cmax, but it can alter the input function from which those parameters emerge. The final concentration trajectory also depends on gastric transit, intestinal absorption, bioavailability, distribution, and elimination, so a change in dissolution timing does not map one-to-one onto a specific peak parameter. In a PK model, dissolution can therefore be represented as an input-shaping process that changes the timing and continuity of drug availability before systemic concentration formation. This provides a mechanistic connection between formulation behavior and peak-phase geometry. The broader dissolution process describes this upstream transition without assigning any clinical interpretation to the resulting concentration curve.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Rising-Phase Rate | Approach to peak. | absorption |
| Input Timing | Early concentration geometry. | dissolution |
Tmax is the time coordinate at which the modeled plasma concentration reaches its maximum value within a defined concentration–time trajectory. It acts as the temporal reference point for peak-window analysis because it identifies where the ascending phase transitions into the declining phase. Before Tmax, the net concentration derivative is positive; at the maximum, the derivative approaches zero; after Tmax, the derivative becomes negative as disposition exceeds the remaining systemic input. Tmax therefore reflects the balance between absorption and disposition rather than a single isolated physiological event. Changes in input timing, absorption rate, bioavailability, distribution, or metabolic clearance can alter this balance and consequently shift the temporal position of the maximum. Tmax should be separated conceptually from Cmax: Tmax describes when the peak occurs, whereas Cmax describes its magnitude. A trajectory can therefore have a similar Cmax with a different Tmax, or a different Cmax with a similar Tmax. The peak window is built from both dimensions together, plus the slopes and curvature surrounding the maximum. In mechanistic reporting, Tmax is thus a temporal PK descriptor rather than a measure of clinical timing, therapeutic onset, or response quality.
Absorption rate is a major determinant of the temporal location of Tmax because it controls how rapidly systemic input accumulates during the ascending phase. A faster input function can move the concentration trajectory toward its maximum earlier, while a slower or more distributed input can extend the rising phase. Distribution also contributes because transfer from the central compartment into peripheral spaces can occur while absorption is still supplying drug. The resulting concentration maximum is reached when the combined disposition processes sufficiently offset the continuing input. Consequently, Tmax reflects the integrated behavior of absorption and disposition rather than absorption alone. A distribution phase can alter the central concentration curve by changing how much drug remains available within the measured compartment at each time point. This can influence both the slope approaching the maximum and the onset of the subsequent decline. In compartmental models, Tmax can therefore shift when distributional exchange rates change even if the nominal input function is unchanged. The relationship is especially important when interpreting peak geometry because a temporal shift does not necessarily indicate a proportional change in peak magnitude. The distribution framework helps separate central concentration timing from the broader movement of drug among compartments.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Tmax Timing | Peak-time descriptor. | tmax |
| Rate → Tmax | Temporal shift. | distribution |
Cmax is the maximum concentration reached by sildenafil within the modeled concentration–time trajectory. It provides the vertical magnitude coordinate of peak-window geometry and is therefore conceptually distinct from Tmax, which provides the temporal coordinate. Cmax is formed through the combined influence of the amount entering systemic circulation, the rate at which that amount enters, and the simultaneous removal or redistribution of drug from the central compartment. A greater systemic input over a defined interval can increase the concentration trajectory, but the final maximum is constrained by disposition occurring at the same time. Distribution can lower central concentration during the rising phase by transferring drug into peripheral compartments, while metabolism and elimination progressively remove drug from the system. Cmax consequently reflects an input–disposition balance rather than absorption extent alone. The peak magnitude also does not define the width of the peak region because width depends on the slopes and curvature around the maximum. Two concentration curves can reach different Cmax values while having similar Tmax values, or reach comparable Cmax values through different temporal trajectories. The Cmax descriptor is therefore most informative when interpreted alongside Tmax, rising-phase slope, distribution, and decline kinetics within the same mechanistic model.
The extent of systemic availability contributes to Cmax by determining how much sildenafil enters the circulating compartment, while the timing of that entry determines how concentrated the input is over time. Bioavailability therefore affects the amount available to form the concentration trajectory, but Cmax remains a composite parameter because distribution and elimination operate simultaneously with absorption. If systemic input is concentrated into a narrower temporal interval, the central concentration can rise more sharply and reach a higher local maximum than would occur with the same total input distributed over a longer interval. Conversely, a broader input function can distribute the same amount across time and alter the height and curvature of the peak. Distribution further shapes the magnitude observed in the central compartment by transferring drug into peripheral spaces and later allowing redistribution. These processes mean that Cmax cannot be treated as a direct synonym for dose input, absorption extent, or any pharmacodynamic quantity. It is the maximum concentration produced by the entire PK system. The bioavailability framework provides the mechanistic context for systemic availability, while Cmax remains the resulting peak concentration descriptor within the concentration–time trajectory.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Cmax Magnitude | Peak concentration. | cmax |
| Extent → Cmax | Magnitude formation. | bioavailability |
Distribution affects peak persistence by changing the movement of sildenafil between the central compartment and peripheral compartments during and after the concentration maximum. While systemic input continues, distribution can remove drug from the central compartment and thereby influence the height and shape of the rising concentration curve. Around Tmax, the distribution process may still be active, meaning the concentration maximum can occur before complete equilibration between compartments. After the maximum, redistribution can contribute to the observed central concentration trajectory as concentration gradients change. This can modify the apparent steepness of decline and the duration over which concentrations remain near the peak region. The effect is therefore dynamic rather than a fixed adjustment to Cmax. Distribution volume, intercompartmental transfer rates, and tissue partitioning characteristics can all influence the relationship between central and peripheral concentrations. In a compartmental model, these factors determine how quickly concentration changes propagate between compartments and how strongly peripheral storage contributes to later central concentrations. The peak-phase structure is consequently a property of the whole distribution system, not merely the initial plasma concentration. The distribution process provides the mechanistic basis for separating peak concentration formation from subsequent redistribution and decline.
Peak-window width can be considered the temporal extent over which the concentration trajectory remains geometrically close to its maximum or transitions gradually from the ascending phase into the declining phase. Distribution can influence this width by modifying the rate at which central concentration changes after the maximum. Rapid transfer between compartments may produce a distinct distribution phase followed by a later decline, whereas slower equilibration can spread concentration changes over a longer interval. Redistribution can also partially offset the decline in the central compartment by returning drug from peripheral spaces, depending on the compartmental structure and concentration gradients. These effects do not create additional systemic input; they alter the internal movement of drug after it has entered the body. A peak therefore can appear sharper or broader depending on how absorption, distribution, and elimination interact around the maximum. The PK trajectory must be interpreted as a continuous system in which multiple processes overlap rather than as isolated phases with rigid boundaries. The PK summary framework integrates absorption, distribution, metabolism, and elimination so that peak persistence can be understood as a property of the complete concentration–time system.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Distribution Influence | Peak persistence. | distribution |
| Redistribution | Peak-window width. | pk summary |
Concentration–effect coupling describes how a sildenafil concentration trajectory is translated into a modeled pharmacodynamic trajectory. Within the peak window, the rising concentration phase can produce a corresponding increase in the modeled PD signal when the specified concentration–effect function is monotonic. As concentration approaches Cmax, the modeled response can approach the corresponding region of the concentration–effect function, depending on its shape and parameters. The relationship is not necessarily linear: receptor or enzyme interaction models may include saturation, nonlinear scaling, or other forms of concentration dependence. As a result, the temporal geometry of a modeled PD peak does not have to match the plasma concentration peak exactly. A concentration maximum at Tmax can be followed by a PD trajectory that changes differently if the model contains temporal coupling, indirect pathway behavior, or nonlinear concentration–effect relationships. For a direct concentration-driven representation, the PD trajectory may closely track concentration, while more complex models can introduce a distinct geometry. The peak window should therefore be described as a coupled PK/PD construct rather than as a single concentration parameter. The PD summary provides the mechanistic framework for interpreting how concentration is translated into modeled pharmacodynamic behavior.
PD geometry during the peak phase depends on the parameters that map concentration into pathway or target activity. Even when the underlying concentration–time trajectory is fixed, changing the concentration–effect relationship can alter the magnitude, curvature, or apparent persistence of the modeled PD signal. Conversely, changes in absorption, distribution, or metabolism can reshape the concentration curve before any PD mapping occurs. This creates two distinct sources of peak-window variation: PK variation changes the concentration input to the PD system, while PD variation changes how that concentration is interpreted by the modeled effect system. A steep concentration rise can therefore produce different modeled PD geometries depending on concentration–effect sensitivity and saturation parameters. Similarly, a broad concentration peak can map onto a comparatively compressed or extended PD trajectory depending on the specified coupling function. These distinctions prevent Cmax from being treated as a direct measurement of PD peak magnitude. The relationship must instead be modeled explicitly from concentration to pathway response. The PD variability framework describes how differences in concentration–effect coupling can alter modeled pharmacodynamic geometry without converting those differences into clinical outcome claims.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Concentration–Effect Coupling | Peak-phase PD. | pd summary |
| PD Variability | Responsiveness variability. | pd variability |
Absorption variability changes the input function that generates the rising phase of the sildenafil concentration–time trajectory. Differences in dissolution timing, gastrointestinal transit, absorption rate, or the temporal distribution of intestinal input can alter how quickly concentration approaches its maximum. A more concentrated input can produce a steeper rising phase, while a distributed input can broaden the approach to Tmax. Because absorption operates simultaneously with distribution and elimination, even a change in input rate can affect both Cmax magnitude and Tmax timing through the altered balance between input and disposition. Absorption variability can therefore change peak-window geometry without requiring a separate change in the underlying PD system. The same total systemic input can produce different concentration curves when its timing differs, because concentration is governed by both the amount entering the system and the rate at which it enters. The resulting differences can appear as shifts in Tmax, changes in Cmax, altered rising-phase curvature, or changes in the temporal width surrounding the maximum. These are PK descriptors rather than clinical outcomes. The PK variability framework captures this input-driven component of peak variation by separating variability in absorption from variability introduced later by distribution, metabolism, and elimination.
Distribution variability can modify the peak window by changing the exchange of sildenafil between central and peripheral compartments. Differences in distribution volume, intercompartmental transfer, or equilibration timing can alter the amount of drug remaining in the central compartment during the rising phase and around Tmax. This can influence Cmax magnitude, peak curvature, and the rate of post-peak decline. Distribution can also contribute to broader concentration persistence when redistribution from peripheral compartments continues after the central concentration maximum. Consequently, a peak-window difference does not necessarily originate from absorption or metabolism; it may reflect differences in how the central and peripheral compartments interact over time. In a compartmental representation, the observed plasma concentration is the result of multiple simultaneous transfers rather than a single isolated process. Distribution variability therefore affects the geometry of the concentration curve by modifying both the ascending and descending regions. It may shift Tmax, alter Cmax, or change the apparent width of the peak region without directly changing the amount originally introduced into the systemic system. The PK variability framework places these distributional effects within the broader set of determinants that shape concentration–time geometry.
Metabolism variability changes the decline component of the concentration–time trajectory and can therefore influence peak formation whenever metabolic clearance is already active during the rising phase. Sildenafil is metabolized substantially through CYP3A4, so differences in metabolic turnover can alter the rate at which drug is removed while absorption and distribution are still occurring. Faster metabolic clearance can increase the opposing disposition term during the ascending phase, potentially flattening the trajectory or changing the balance at which Tmax occurs. Slower turnover can reduce that opposing component and allow concentration to persist differently around the peak. Because metabolism operates continuously, its influence is not restricted to the post-peak phase. The net concentration trajectory reflects the simultaneous interaction of absorption, distribution, metabolism, and elimination. Metabolic variability can consequently alter Cmax, Tmax, peak curvature, and the subsequent decline without acting as an isolated peak-specific process. The metabolism framework describes the broader clearance process, while CYP3A4 provides the enzyme-level mechanistic context. These effects remain PK descriptors and do not imply any clinical effectiveness or outcome difference.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Variability | Rising-phase variability. | pk variability |
| Distribution Variability | Peak persistence variability. | pk variability |
| Metabolism Variability | Decline variability. | metabolism |
The peak window is a modeled region of the sildenafil PK/PD trajectory surrounding peak concentration formation. It is defined by the approach toward Cmax, the temporal location of Tmax, the curvature of the rising and declining phases, distribution behavior, and the concentration–effect relationship used to generate the PD trajectory. It is therefore broader than a single maximum point. Before the peak, systemic input contributes to an increasing concentration while distribution and elimination simultaneously remove drug. Near Tmax, the net rate of concentration change approaches zero as input and disposition become balanced. After Tmax, disposition exceeds the remaining input and concentration declines. The modeled PD trajectory can follow the concentration curve closely or differ according to the specified concentration–effect coupling. Thus, peak-window geometry describes interacting PK and PD processes rather than a clinical peak or an effectiveness endpoint.
Tmax and Cmax describe two different dimensions of the same concentration–time trajectory. Tmax identifies the time coordinate at which the modeled plasma concentration reaches its maximum, while Cmax identifies the magnitude of that maximum. Tmax therefore provides the temporal position of the peak and Cmax provides its vertical position. Neither parameter alone describes the complete peak window. The slopes approaching and leaving the maximum determine how sharply or broadly the peak is formed, while distribution and elimination influence the post-peak trajectory. Absorption determines much of the input timing and rising-phase structure, but disposition operates simultaneously and contributes to the point at which concentration stops increasing. Consequently, two trajectories can have similar Cmax values with different Tmax values, or similar Tmax values with different Cmax values. Peak-phase geometry requires both descriptors plus the surrounding concentration–time curvature.
Absorption rate influences the peak window by determining how rapidly sildenafil enters the systemic circulation during the ascending portion of the concentration–time trajectory. A faster and more concentrated input can produce a steeper rise, while slower or temporally distributed input can broaden the ascending phase. Because distribution and elimination occur at the same time, the observed concentration curve reflects the balance between incoming drug and simultaneous disposition. A change in absorption rate can therefore shift Tmax, modify Cmax, and alter the curvature surrounding the maximum. Absorption timing also affects how much drug is present in the central compartment when distribution and metabolic clearance are acting. The resulting peak is consequently an input–disposition phenomenon rather than a direct representation of absorption alone. In a mechanistic model, absorption defines an important part of the input function, while the complete peak window emerges from its interaction with distribution, metabolism, elimination, and the concentration–effect relationship.
Distribution behavior shapes peak persistence by controlling movement of sildenafil between the central compartment and peripheral compartments during and after peak formation. While absorption continues, distribution can remove drug from the central compartment and modify the concentration rise. Around Tmax, distribution may remain active, so the plasma maximum can occur before complete equilibration between compartments. After Tmax, redistribution can influence the rate at which central concentration declines as concentration gradients change. The resulting trajectory may therefore have a sharper or broader peak depending on intercompartmental transfer rates, distribution volume, and tissue partitioning characteristics. Distribution does not represent new systemic input; it redistributes drug that has already entered the system. Its contribution to peak persistence is consequently a matter of compartmental movement and concentration gradients. A broad peak region can emerge when central concentration changes gradually because distribution and elimination interact over time. These mechanisms help explain why Cmax alone cannot describe the full temporal structure of the peak.
Peak-window variability can arise from differences in absorption, distribution, metabolism, elimination, and concentration–effect coupling. Absorption variability changes the timing and steepness of the rising phase through differences in dissolution, gastrointestinal input, and systemic entry. Distribution variability changes how much drug remains in the central compartment and how redistribution shapes the post-peak trajectory. Metabolic variability changes clearance while absorption and distribution are still occurring, potentially altering both peak magnitude and timing. These PK processes can shift Tmax, modify Cmax, and change peak curvature or persistence. PD variability adds another layer because the same concentration trajectory can map onto different modeled effect geometries when concentration–effect parameters differ. Peak-window variability is therefore not attributable to a single determinant. It is the combined result of multiple time-dependent processes operating simultaneously. In mechanistic analysis, the concentration–time trajectory should be separated from the concentration–effect mapping so that PK variability and PD variability are not treated as the same phenomenon.